Jingxin Pharmaceutical released its 2026 interim report. Total operating revenue was 1.987 billion yuan, down 1.46% from the same period last year. Net profit attributable to the parent company was 352 million yuan, down 9.35% year-on-year. Net cash inflow from operating activities was 477 million yuan. The asset-liability ratio was 24.07%, gross margin was 50.50%, and diluted earnings per share was 0.43 yuan, down 6.52% year-on-year. The number of shareholders was 32,900, and the top ten shareholders held 46.80% of the total share capital.
Zhejiang Jingxin Pharmaceutical Co LtdNet profit down 9.35% year-on-year in interim report
